FDA Reform Opportunity could generate more than $10 trillion in economic value, according to a new report. The report says faster drug approvals would help patients access lifesaving medicines sooner. It also argues that shorter review timelines would encourage medical innovation, increase competition, and improve treatment availability without changing existing safety standards.
The report estimates that reducing the Food and Drug Administration’s review process by one year could deliver significant economic benefits. It argues that lengthy effectiveness reviews account for much of the approval timeline. According to the findings, shortening those reviews would speed access to drugs, biologics, and medical devices. The report also says faster approvals would encourage additional investment in medical research and development.
According to the report, bringing a new drug through the approval process usually takes about a decade. Most of that time is spent evaluating effectiveness instead of conducting safety testing. The report acknowledges that government oversight remains important for protecting patient safety. However, it questions whether the current effectiveness review process extends approval timelines unnecessarily.
The report also links faster approvals to lower prescription drug costs. Medicines could enter the market sooner under a shorter review process. Increased competition among manufacturers could then improve affordability for patients. The report argues that greater competition would also expand treatment choices.
Researchers estimate that reducing approval timelines by one to six years could generate trillions of dollars in economic value. Earlier access to innovative medicines could improve patient outcomes. Faster approvals could also strengthen incentives for continued pharmaceutical research. According to the report, these changes would benefit both public health and long-term economic growth.
The report also highlights growing international competition. It argues that China’s faster and lower-cost clinical trial system could attract pharmaceutical investment away from the United States. The authors believe policymakers should reconsider the pace of the current approval process to remain globally competitive.
Another recommendation involves adopting an approach similar to the accelerated development model used during the COVID-19 pandemic. The report argues that patients with other serious diseases could also benefit from faster regulatory pathways. It adds that appropriate safety safeguards should remain in place throughout the process.
The report outlines several proposals to modernize the review system. These include expanding the use of artificial intelligence during drug evaluations. It also recommends more efficient clinical trial designs and broader access to existing “right to try” programs. According to the report, these measures could reduce unnecessary delays while maintaining regulatory oversight.
The report concludes that FDA Reform Opportunity could strengthen medical research and improve patient access to innovative treatments. It also says carefully designed reforms could preserve safety standards while reducing approval timelines. According to the report, FDA Reform Opportunity would support economic growth and strengthen the nation’s position in global medical innovation if the review system is modernized.
